AVIPTADIL; Class effect of a Synthetic VIP as a treatment option in COVID 19 patients with severe respiratory failure
Despite dynamic drug and vaccine developmental processes to reduce the disease burden of COVID 19, still the options for treatment are very limited. Vasoactive peptide (VIP) has diversified physiological action with specific features of lung protection-related activities. VIP inhibits SARS COV-2 gen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Turaz Bilim
2022-03-01
|
| Series: | Medicine Science |
| Subjects: | |
| Online Access: | http://www.ejmanager.com/fulltextpdf.php?mno=133076 |